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Immunotherapies using T cells transduced with a chi-
meric antigen receptor (CAR) gene have been demon-
strated as a promising strategy for cancer treatment.
CAR-T cells can specifically recognize tumor antigen
expressed on the cell surface and eliminate tumors.
Although CAR-T cell therapies for hematological malig-
nancies targeting CD19 have recently showed promising
clinical outcomes, few success cases have been reported
for solid tumors because of the lack of specific cell sur-
face antigens. Glypican-1 (GPC-1) is the member of the
glypican family of heparin sulfate proteoglycans that are
attached to the cell surface by a glycosylphosphatidyli-
nositol (GPI) anchor. We have previously found GPC-1
were preferentially expressed in squamous cell carci-
noma including esophageal cancers, lung cancers, and
cervical cancers, and played an important role in cancer
growth. We have developed monoclonal antibodies
against GPC-1 having in vivo anti-tumor effects. In this
study, we have developed anti-GPC-1-CAR-T cells and
explored their potential for squamous cell carcinoma
treatment. The retroviral expression vectors containing
the CAR gene consisting of variable regions of the anti-
GPC-1 mAb, and CD3ζ/CD28 intracellular signaling
domains were generated, and we transduced it into
human peripheral blood T cells. The generated anti-
GPC-1 CAR-T cells were activated and propagated by
IL2 and anti-CD3 Ab. Purified CD8+ anti-GPC-1 CAR-
T cells specifically recognized GPC-1 expressed on can-
cer cells, produced high amount of IFN-g and TNF-a,
and showed high cytotoxic activities. Purified CD4+
anti-GPC-1 CAR-T cells also showed the production of
Th1 and Th2 cytokines and cytotoxic activities in a
GPC-1-specific manner. These results indicate that
GPC1-targeted CAR-T cells have a strong ability to
eliminate cancer cells and may be an attractive strategy
for treatment of patients with squamous cell carcinoma.
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